Asset Details
Do you wish to reserve the book?
Global distribution and temporal analysis of R70Q/H oncogenic mutations in hepatitis C virus subtype 1b core protein
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Global distribution and temporal analysis of R70Q/H oncogenic mutations in hepatitis C virus subtype 1b core protein
Do you wish to request the book?
Global distribution and temporal analysis of R70Q/H oncogenic mutations in hepatitis C virus subtype 1b core protein
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Global distribution and temporal analysis of R70Q/H oncogenic mutations in hepatitis C virus subtype 1b core protein
2025
Overview
The hepatitis C virus (HCV) core protein is crucial in viral pathogenesis and hepatocarcinogenesis. Amino acid substitutions at position 70, particularly R70Q and R70H, are associated with an increased risk of hepatocellular carcinoma (HCC) and partial resistance to interferon-based therapy in genotype 1b infections. However, the global and temporal dynamics of these oncogenic mutations remain poorly understood. In this study, we analyzed 3,218 publicly available HCV subtype 1b core sequences to investigate the global distribution of R70Q/H mutations and their evolution across therapeutic eras. Our findings reveal notable regional disparities, with R70Q prevalence highest in Western Europe (77.4%) and Northern America (70.4%), while R70H was most frequent in Central America (45%). Temporal analysis of 1,351 dated sequences showed a significant decline in R70Q/H frequency during the pegylated interferon plus ribavirin era (2001–2010: 24%) compared to the conventional interferon period (1989–2000: 39%; p = 0.0081), followed by a resurgence in the direct-acting antivirals (DAAs) era (2014–present: 43%; p = 0.0183). These temporal shifts, including both the decline and resurgence, suggest a complex interplay between treatment-related selective forces, viral diversity, host factors, and possibly sampling bias. Our results underscore the need for regional molecular surveillance to guide HCC monitoring in HCV subtype 1b patients with R70Q/H mutations, even after viral clearance, and to inform targeted prevention strategies in high-prevalence areas.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
/ Antiviral Agents - therapeutic use
/ Carcinoma, Hepatocellular - virology
/ Cellular and Infection Microbiology
/ Datasets
/ Drug Resistance, Viral - genetics
/ Genotype
/ HCV
/ Hepacivirus - classification
/ Hepatitis C, Chronic - drug therapy
/ Hepatitis C, Chronic - virology
/ Humans
/ Interferons - therapeutic use
/ Mutation
/ Proteins
/ Regions
